Fatemeh Dehghanian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fatemeh Dehghanian has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Elham Jafari
Pathology and Stem Cell Research Center, Kerman University of Medical Sciences, Kerman, Iran
2 shared publications - Mohammad Khaksari
Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran
2 shared publications - Nazanin Sabet
Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
2 shared publications - Zahra Soltani
Endocrinology and Metabolism Research Center, Kerman University of Medical Sciences, Kerman, Iran
2 shared publications - Ali Derakhshani
Research Center for Hydatid Disease in Iran, Kerman University of Medical Sciences, Kerman, Iran
1 shared publication - Alireza Farsinejad
Department of Hematology and Laboratory Sciences, Faculty of Allied Medical Sciences, Kerman University of Medical Sciences, Kerman, Iran
1 shared publication
Latest Publications
- Open Access
- 10 November 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 8235961
The Prescription of Oral Mucosal Mesenchymal Stem Cells post‐Traumatic Brain Injury Improved the Kidney and Heart Inflammation and Oxidative Stress
Background. In the last years, mesenchymal stem cells (MSCs) have been considered as a useful strategy to treat many diseases such as traumatic brain injury (TBI). The production of inflammatory agents by TBI elicits an inflammatory response directed to other systems of body, such as the heart and the kidneys. In this study, the efficacy of oral mucosal mesenchymal stem cells (OMSCs) prescription after TBI in inflammation and oxidative stress of the heart and kidneys was evaluated. Methods. Twenty‐four male rats were located in groups as follows: sham, TBI, vehicle (Veh), and stem cell (SC). OMSCs were injected intravenously 1 and 24 hours after TBI. Inflammatory, oxidative stress, and histopathological outcomes of the heart and kidney tissues were investigated 48 hours after TBI. Results. TBI caused an increase in the level of interleukin‐1β (IL‐1β), interleukin‐6 (IL‐6), malondialdehyde (MDA), and carbonyl protein (PC) of the heart and kidney compared to the sham group. Superoxide dismutase (SOD), total antioxidant capacity (TAC), catalase (CAT), and interleukin‐10 (IL‐10) of the heart and kidney decreased after TBI. The use of OMSCs after TBI reduced the changes of these factors in both the heart and the kidney. Conclusion. Application of OMSCs after TBI can decrease inflammation and oxidative stress of the heart and kidney tissues leading to the reduction of damage. Therefore, this method can be evaluated in the TBI patients in future studies.
- 10 November 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 8235961
Open AccessThe Prescription of Oral Mucosal Mesenchymal Stem Cells post‐Traumatic Brain Injury Improved the Kidney and Heart Inflammation and Oxidative Stress
Background. In the last years, mesenchymal stem cells (MSCs) have been considered as a useful strategy to treat many diseases such as traumatic brain injury (TBI). The production of inflammatory agents by TBI elicits an inflammatory response directed to other systems of body, such as the heart and the kidneys. In this study, the efficacy of oral mucosal mesenchymal stem cells (OMSCs) prescription after TBI in inflammation and oxidative stress of the heart and kidneys was evaluated. Methods. Twenty‐four male rats were located in groups as follows: sham, TBI, vehicle (Veh), and stem cell (SC). OMSCs were injected intravenously 1 and 24 hours after TBI. Inflammatory, oxidative stress, and histopathological outcomes of the heart and kidney tissues were investigated 48 hours after TBI. Results. TBI caused an increase in the level of interleukin‐1β (IL‐1β), interleukin‐6 (IL‐6), malondialdehyde (MDA), and carbonyl protein (PC) of the heart and kidney compared to the sham group. Superoxide dismutase (SOD), total antioxidant capacity (TAC), catalase (CAT), and interleukin‐10 (IL‐10) of the heart and kidney decreased after TBI. The use of OMSCs after TBI reduced the changes of these factors in both the heart and the kidney. Conclusion. Application of OMSCs after TBI can decrease inflammation and oxidative stress of the heart and kidney tissues leading to the reduction of damage. Therefore, this method can be evaluated in the TBI patients in future studies.
- Open Access
- 1 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 4065118
The Effect of Oral Mucosal Mesenchymal Stem Cells on Pathological and Long‐Term Outcomes in Experimental Traumatic Brain Injury
Background. Neuroprotective effects of stem cells have been shown in some neurologic diseases. In this study, the effect of oral mucosal mesenchymal stem cells (OMSCs) on traumatic brain injury (TBI) was evaluated in long term. Materials and Methods. TBI was induced by Marmarou’s method. The number of 2 × 106 OMSCs was intravenously injected 1 and 24 h after the injury. Brain edema and pathological outcome were assessed at 24 h and 21 days after the injury. Besides, long‐term neurological, motor, and cognitive outcomes were evaluated at days 3, 7, 14, and 21 after the injury. Results. OMSCs administration could significantly inhibit microglia proliferation, and reduce brain edema and neuronal damage, at 24 h and 21 days after the injury. Neurological function improvement was observed in the times evaluated in OMSCs group. Cognitive and motor function dysfunction and anxiety‐like behavior were prevented especially at 14 and 21 days after the injury in the treatment group. Conclusion. According to the results of this study, OMSCs administration after TBI reduced brain edema and neuronal damage, improved neurologic outcome, and prevented memory and motor impairments and anxiety‐like behavior in long term.
- 1 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 4065118
Open AccessThe Effect of Oral Mucosal Mesenchymal Stem Cells on Pathological and Long‐Term Outcomes in Experimental Traumatic Brain Injury
Background. Neuroprotective effects of stem cells have been shown in some neurologic diseases. In this study, the effect of oral mucosal mesenchymal stem cells (OMSCs) on traumatic brain injury (TBI) was evaluated in long term. Materials and Methods. TBI was induced by Marmarou’s method. The number of 2 × 106 OMSCs was intravenously injected 1 and 24 h after the injury. Brain edema and pathological outcome were assessed at 24 h and 21 days after the injury. Besides, long‐term neurological, motor, and cognitive outcomes were evaluated at days 3, 7, 14, and 21 after the injury. Results. OMSCs administration could significantly inhibit microglia proliferation, and reduce brain edema and neuronal damage, at 24 h and 21 days after the injury. Neurological function improvement was observed in the times evaluated in OMSCs group. Cognitive and motor function dysfunction and anxiety‐like behavior were prevented especially at 14 and 21 days after the injury in the treatment group. Conclusion. According to the results of this study, OMSCs administration after TBI reduced brain edema and neuronal damage, improved neurologic outcome, and prevented memory and motor impairments and anxiety‐like behavior in long term.